Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|July 17, 2023
In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathwayEmma Ispasanie, Lukas Muri, Marc Schmid, et al.
Clinical & Translational Immunology|September 5, 2017
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infectionsMichael Kammüller, Tsen-Fang Tsai, Christopher Em Griffiths, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 10, 2012
Investigative safety science as a competitive advantage for PharmaJonathan Moggs, Pierre Moulin, Francois Pognan, et al.
Immunology|April 13, 2022
Therapeutic antibody glycosylation impacts antigen recognition and immunogenicityBabette Wolf, Mateusz Piksa, Isabelle Beley, et al.
Blood Advances|January 4, 2018
T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasiaTina Rubic-Schneider, Masataka Kuwana, Brigitte Christen, et al.
Journal of Pharmaceutical Sciences|February 2, 2023
An Intra-Company Analysis of Inherent Particles in Biologicals Shapes the Protein Particle Mitigation Strategy Across Development StagesSorina Morar-Mitrica, Thomas Pohl, Dietmar Theisen, et al.
Journal of Leukocyte Biology|January 6, 2016
Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasisNatasha Whibley, Elaine Tritto, Elisabetta Traggiai, et al.
Allergy|July 29, 2023
Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-desmethyl naproxen metabolite but not the acyl glucuronidePaul Thomson, Nik Fragkas, Laila M Kafu, et al.
Scientific Reports|November 18, 2016
Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralizationNoria Segueni, Elaine Tritto, Marie-Laure Bourigault, et al.
Plos Pathogens|April 7, 2020
Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized miceNicole Caduff, Donal McHugh, Anita Murer, et al.
Pageof 3